Table 1 Patients’ characteristics and pre- and intraoperative variables of both groups
Successful group (n:48) | Unsuccessful group (n:68) | P value | |
|---|---|---|---|
Sex (n, %) | |||
Male | 23 (42,5%) | 31 (57,5%) | 0,804 |
Female | 25 (40,3%) | 37 (59,7%) | |
Age (years) | 38.5 (10–68) | 33.4 (16–56) | 0,03 |
End stage renal failure etiology (n, %) | |||
Vesicoureteral reflux | 8 (16,6) | 10 (14,7) | |
Nephrolithiasis | 6 (12,5) | 9 (13,2) | |
Pyelonephritis | 4 (8,3) | 7 (10,2) | |
Polycystic kidney disease | 4 (8,3) | 6 (8) | |
Others (HT, DM, CHK, NS) | 26 (54,1) | 36 (52) | |
Preoperative vesicoureteral reflux grade (n, %) | |||
Grade 1 | 2 (4) | 1 (1,4) | 0,087 |
Grade 2 | 3 (6) | 5 (3,4) | |
Grade 3 | 15 (31) | 17 (11,5) | |
Grade 4 | 25 (52) | 29 (19,7) | |
Grade 5 | 3 (6) | 16 (10,8) | |
Ureteral diameter ratio, median (min–max) | 0,13 (0.08–0.22) | 0,17 (0.08–0.35) | < 0,001 |
Pre-injection visual assessment | |||
Favorable for injection | 43 (57,3%) | 32 (42,7%) | < 0,001 |
Unfavorable for injection | 5 (12,2%) | 36 (87,8%) | |
Post-injection volcano-shaped mound view; | |||
Yes (proper coaptation) | 43 (53%) | 38 (47%) | < 0,001 |
No (improper coaptation) | 5 (14,3%) | 30 (85,7%) | |
The volume of the bulking agent (milliliters) | 1,64 (± 0,56) | 1,77 (± 0,55) | 0,222 |
Follow-up period after injection (months), Median (min- max) | 52 (6–103) | 53,5 (8–109) | 0,092 |